Apply for Research Grants in Multimodal Surveillance in Heart Tx, Noninvasive Biomarkers in Lung Tx, and Early Detection of BOS
ISHLT is now accepting applications for three new research grants funded by the ISHLT Foundation. Applications for these grants will be accepted until Friday, 29 September at 11:59 p.m. ET/Saturday, 30 September at 03:59 UTC. You must be an ISHLT member to apply.
Full details about award eligibility and application criteria are available on the ISHLT website.
ISHLT Multimodality Research on Heart Transplant Patient Care Grant, Supported by CareDx
Two
$40,000 grants will be awarded—one to a United States-based recipient, and one to a recipient from outside the United States. The award will fund research focusing on improving heart transplant patient care.
Winning research will investigate the combined use of donor-derived cell-free DNA (dd-cfDNA) and gene expression profiling (GEP) for enhanced surveillance strategies. Research should harness genomic medicine techniques to achieve early and accurate detection of allograft injury and rejection in heart transplant recipients. The research may also explore the potential of these techniques in guiding immunosuppression and rejection treatment. The ultimate goal is to improve outcomes, increase graft survival, reduce mortality and morbidity, enhance quality of life, and optimize healthcare costs related to heart transplantation.
ISHLT Noninvasive Biomarker Research on Lung Transplant Patient Care with Donor-Derived Cell-Free DNA Grant, Supported by CareDx
Two $40,000 grants will be awarded—one to a United States-based recipient, and one to a recipient from outside the United States. The award will fund research that specifically investigates the utility of donor-derived cell-free DNA
(dd-cfDNA) as a measure of allograft injury and rejection in lung transplant recipients.
By utilizing genomic medicine, winning research will explore ways to enhance the early detection of allograft injury and rejection, allowing for timely interventions and improved outcomes. Research may also explore the potential of dd-cfDNA as a noninvasive tool for monitoring graft health, guiding immunosuppression, and optimizing rejection treatment. The ultimate goal is to reduce mortality and morbidity, increase graft survival, improve quality of life, and minimize healthcare costs associated with lung transplantation.
ISHLT Pulmonary Function Test/Spirometry and Co-Relationships with Lung Transplantation and BOS Research Grant, Supported by Zambon
One $20,000 grant will be awarded to fund research that enhances understanding of the relationship between pulmonary function testing, lung transplantation, and Bronchiolitis Obliterans Syndrome (BOS).
The research will focus on identifying novel methods for early detection and monitoring of BOS using pulmonary function testing, investigating the disease's impact on lung function, and understanding the trajectories of lung function decline
in BOS patients. By filling knowledge gaps, winning research will improve diagnosis, treatment, and outcomes for individuals with BOS.